Characteristics | Center 1 (N = 82) | Center 2 (n = 124) | Center 3 (n = 161) | P -value b | ||
---|---|---|---|---|---|---|
AD patients | ||||||
Number of subjects (%) | 37 (45.1) | 73 (58.9) | 50 (31.1) | <0.001 | ||
Age (yr), mean (SD) | 68.9 (8.6) | 67.0 (9.5) | 68.5 (10.7) | 0.54 | ||
Women, n (%) | 27 (73.0) | 39 (53.4) | 31 (62.0) | 0.14 | ||
MMSE, mean (SD) | 18.6 (6.5) | 19.5 (6.3) | 22.8 (4.9) | 0.003 | ||
CSF biomarkers, pg/ml, mean (SD) | ||||||
Total tau | 599.5 (281.2) | 774.2 (370.7) | 539.6 (315.2) | <0.001 | ||
p-tau181 | 79.4 (24.4) | 101.5 (42.2) | 80.0 (39.2) | 0.002 | ||
Aβ42 | 656.9 (257.1) | 603.2 (245.4) | 772.5 (363.5) | 0.008 | ||
Aβ40 | 16,229.7 (6,252.8) | 13,426.8 (5,250.9) | 20,814.3 (12,114.6) | <0.001 | ||
Aβ 42/40 | 0.044 (0.018) | 0.049 (0.021) | 0.045 (0.025) | 0.39 | ||
Non-AD patients | ||||||
Number of subjects (%) | 45 (54.9) | 51 (41.1) | 111 (68.9) | <0.001 | ||
Age (yr), mean (SD) | 63.3 (10.7) | 64.4 (10.6) | 65.0 (11.8) | 0.70 | ||
Women, n (%) | 17 (37.8) | 20 (40.0) | 56 (50.4) | 0.25 | ||
MMSE, mean (SD) | 23.7 (4.9) | 20.9 (6.1) | 24.7 (5.3) | <0.001 | ||
CSF biomarkers (pg/ml), mean (SD) | ||||||
Total tau | 201.5 (64.0) | 283.8 (150.5) | 308.6 (248.6) | 0.01 | ||
p-tau181 | 40.4 (12.8) | 46.2 (15.8) | 40.8 (19.7) | 0.14 | ||
Aβ42 | 984.3 (253.6) | 987.0 (344.7) | 1,039.3 (343.3) | 0.50 | ||
Aβ40 | 12,219.5 (4,775.2) | 11,161.0 (4,955.5) | 17307.2 (9,952.7) | <0.001 | ||
Aβ 42/40 | 0.087 (0.024) | 0.098 (0.041) | 0.077 (0.066) | 0.06 |